International Journal of
Molecular Sciences Article
Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients Tomoko Mizushige 1 , Hiroyuki Kobori 1,2,3, *, Hirofumi Hitomi 1 , Yoko Nishijima 4 , Fumihiro Tomoda 5 , Satoshi Morimoto 6 , Masakazu Kohno 4 and Akira Nishiyama 1 1 2 3 4 5 6
*
Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan; [email protected] (T.M.); [email protected] (H.H.); [email protected] (A.N.) Departments of Pharmacology and of Nephrology, School of Medicine, International University of Health and Welfare, Tokyo 107-0062, Japan Departments of Physiology and of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA Department of Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan; [email protected] (Y.N.); [email protected] (M.K.) The Second Department of Internal Medicine, Toyama University School of Medicine, Toyama 930-0194, Japan; [email protected] The Second Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, Japan; [email protected] Correspondence: [email protected]; Tel.: +81-(0)3-6406-8630
Academic Editor: Alan Parrish Received: 22 June 2016; Accepted: 19 August 2016; Published: 27 October 2016
Abstract: This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (
Molecular Sciences Article
Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients Tomoko Mizushige 1 , Hiroyuki Kobori 1,2,3, *, Hirofumi Hitomi 1 , Yoko Nishijima 4 , Fumihiro Tomoda 5 , Satoshi Morimoto 6 , Masakazu Kohno 4 and Akira Nishiyama 1 1 2 3 4 5 6
*
Department of Pharmacology, Kagawa University School of Medicine, Kagawa 761-0793, Japan; [email protected] (T.M.); [email protected] (H.H.); [email protected] (A.N.) Departments of Pharmacology and of Nephrology, School of Medicine, International University of Health and Welfare, Tokyo 107-0062, Japan Departments of Physiology and of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA Department of Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan; [email protected] (Y.N.); [email protected] (M.K.) The Second Department of Internal Medicine, Toyama University School of Medicine, Toyama 930-0194, Japan; [email protected] The Second Department of Internal Medicine, Kansai Medical University, Osaka 573-1010, Japan; [email protected] Correspondence: [email protected]; Tel.: +81-(0)3-6406-8630
Academic Editor: Alan Parrish Received: 22 June 2016; Accepted: 19 August 2016; Published: 27 October 2016
Abstract: This study was performed to demonstrate urinary angiotensinogen as a potential prognostic marker of the albuminuria reduction effects of olmesartan in patients with metabolic syndrome. In 24 patients (eight women, 57.88 ± 2.00 years), 5–40 mg/day of olmesartan were given. Urinary concentrations of albumin and angiotensinogen (normalized by urinary concentrations of creatinine) and plasma renin activity were measured before and after the 12- and 24-week marks of olmesartan treatment. Olmesartan treatment increased plasma renin activity and decreased urinary albumin and urinary angiotensinogen significantly (p < 0.05). Based on the % change in urinary albumin, patients were divided into two groups, responders (
